Código QR (código de barras bidimensional)

Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason

ObjectiveBiosimilars represent a new opportunity for inflammatory bowel disease (IBD) treatment and economic sustainability of therapies. This study aimed to evaluate the efficacy and long-term safety of the adalimumab biosimilar ABP 501 in biologic-naïve vs. biologic-switched IBD patients.MethodsA...

Fuld beskrivelse

Na minha lista:
Principais autores: Giammarco Mocci, Arianna Cingolani, Giorgia Orrù, Carla Felice, Francesca Maria Onidi, Gianmarco Lombardi, Davide Checchin, Raffaele Colucci, Laurino Grossi, Antonio Ferronato, Chiara Rocchi, Marta Ascolani, Paolo Usai Satta, Lucia Fanini, Stefano Pilati, Antonio Tursi
Format: Artigo
Sprog:Inglês
Udgivet: Frontiers Media S.A. 2023-10-01
Serier:Frontiers in Gastroenterology
Fag:
adalimumab
ABP 501
biosimilar
Crohn’s disease
ulcerative colitis
Online adgang:https://www.frontiersin.org/articles/10.3389/fgstr.2023.1218228/full
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker